BBS12: A Drug Target / Disease Biomarker (G166379)
BBS12: A Drug Target / Disease Biomarker
BBS12 is a protein that is expressed in the brain and is known for its role in the regulation of cell survival and proliferation. It has also been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease and Parkinson's disease. As a result, BBS12 has become a focus of interest for researchers as a potential drug target or biomarker.
The research on BBS12 began in the 1990s, when scientists discovered that the protein was highly expressed in the brain and that it was involved in the regulation of neuronal survival and proliferation. Since then, several studies have confirmed the involvement of BBS12 in the development and progression of neurological disorders.
One of the most significant findings was the observation that individuals with certain genetic mutations, such as those in the neurodegenerative disorder Alzheimer's disease, had reduced levels of BBS12 in their brains. This suggests that BBS12 may be a potential drug target or biomarker for this disease, as drugs that target this protein may be effective in treating Alzheimer's disease.
Another promising aspect of BBS12 research is its potential as a therapeutic target for other neurological disorders, such as Parkinson's disease and multiple sclerosis. Studies have shown that BBS12 is highly expressed in the brains of individuals with these conditions and that it is involved in the development and progression of these disorders.
In addition to its potential as a drug target or biomarker, BBS12 has also been shown to be involved in the regulation of cellular processes that are important for brain function. For example, studies have shown that BBS12 is involved in the regulation of the formation and stability of neural connections, which are critical for the transmission of signals in the brain.
Overall, the research on BBS12 is still in its early stages, but it is clear that this protein is of great interest as a potential drug target or biomarker for a variety of neurological disorders. Further research is needed to fully understand its role and to develop treatments that target this protein.
Protein Name: Bardet-Biedl Syndrome 12
Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis. As part of the TRiC complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia (PubMed:20080638). Involved in adipogenic differentiation (PubMed:19190184)
More Common Targets
BBS2 | BBS4 | BBS5 | BBS7 | BBS9 | BBSome complex | BBX | BCAM | BCAN | BCAN-AS1 | BCAP29 | BCAP31 | BCAR1 | BCAR3 | BCAR3-AS1 | BCAR4 | BCAS1 | BCAS2 | BCAS2P2 | BCAS3 | BCAS4 | BCAT1 | BCAT2 | BCCIP | BCDIN3D | BCDIN3D-AS1 | BCHE | BCKDHA | BCKDHB | BCKDK | BCL10 | BCL10-AS1 | BCL11A | BCL11B | BCL2 | BCL2A1 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L12 | BCL2L13 | BCL2L14 | BCL2L15 | BCL2L2 | BCL2L2-PABPN1 | BCL3 | BCL6 | BCL6B | BCL7A | BCL7B | BCL7C | BCL9 | BCL9L | BCLAF1 | BCLAF3 | BCO1 | BCO2 | BCOR | BCORL1 | BCORP1 | BCR | BCR(BACURD1) E3 ubiquitin ligase complex | BCR(BACURD3) E3 ubiquitin ligase complex | BCR(KLHL12) E3 ubiquitin ligase complex | BCR(KLHL20) E3 ubiquitin ligase complex | BCR(KLHL22) E3 ubiquitin ligase complex | BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex | BCRP2 | BCRP3 | BCRP4 | BCRP5 | BCRP6 | BCRP7 | BCS1L | BCYRN1 | BDH1 | BDH2 | BDKRB1 | BDKRB2 | BDNF | BDNF-AS | BDP1 | BEAN1 | BEAN1-AS1 | BECN1 | BECN2 | BEGAIN | BEND2 | BEND3 | BEND3P3 | BEND4 | BEND5 | BEND6 | BEND7 | BEST1 | BEST2 | BEST3 | BEST4 | BET1 | BET1L